Darunavir for the treatment of HIV infection

Abstract

Darunavir (DRV) was the last approved protease inhibitor (PI) and has been extensively used for the treatment of HIV in both naïve and experienced subjects due to its high genetic barrier and efficacy. The introduction in clinical practice of integrase strand transfer inhibitors limited its role in the management of naïve subjects and in antiretroviral treatment simplification strategies. However, recent data from trials that have investigated the new DRV/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) combination showed an excellent efficacy and tolerability of this coformulation both in naïve patients and in those with viral suppression, making D/C/F/TAF a new option for the treatment of HIV infection. Areas covered: The authors present and discuss the efficacy and safety data of DRV when used in antiretroviral-naïve, multiexperienced subjects and in the setting of treatment deintensification in subjects with viral suppression. Moreover, the authors evaluate the recent data from two different Phase III trials on D/C/F/TAF both in treatment-naïve and virologically suppressed subjects. Expert opinion: Although novel antiretroviral drugs may become available over time, DRV continues to represent a valuable option for multiexperienced subjects and has a role in simplification regimens. In addition, the convenience of D/C/F/TAF coformulation may be useful for the future management of HIV-infected subjects.

High-throughput Screening and Experimental Identification of Potent Drugs Targeting SARS-CoV-2 Main Protease

“…This study indicated a signi cant a nity for Mpro at the e-4 M level, which should be slightly helpful in suppressing the virus, but a retrospective investigation is needed because it might be di cult to achieve an obvious effect in the body at the conventional dose. Moreover, darunavir, an HIV protease inhibitor 35 , has also been con rmed to suppress SARS-CoV-2 in cellular experiments 33 , but our results showed that its a nity is lower than that of dihydroergotamine and moxi oxacin.…”

COVID‐19 drug repurposing: A review of computational screening methods, clinical trials, and protein interaction assays

“…Darunavir is also a protease inhibitor originally used for HIV 42 . There are not clinical trials concerning the SARS‐CoV‐2 treatment effectiveness of darunavir.…”

Potential treatment methods targeting 2019-nCoV infection

“…Recently, the clinical trials of baricitinib against COVID-19 ( NCT04320277 and NCT04340232 ) are ongoing and the results are eagerly awaited ( Table 2 ). Lanjuan Li team has shown Darunavir ( Table 1 ), a HIV-1 protease inhibitor [ 34 ], has the activity against 2019-nCoV. Darunavir could possibly be administered along with either ritonavir or cobicistat, but the effectiveness and safety profile are yet to be explored.…”